bioRxivPharmacology & ToxicologyPreprint
Red yeast rice-derived MKA ameliorates cardiac hypertrophy in hypertensive rats by inhibiting ERK1/2/c-Fos pathway
Rubin TaniD, Dongqi Yang, Kuntao Liu, Jia LIU, Na LiiD, Manqi Sun, Xiaoqiu TaniD, Qinghua HuiD, Chunxiang ZhangiD
Abstract
BackgroundCardiac hypertrophy is a key pathological process in hypertensive heart failure, yet current antihypertensive therapies do not directly target it. Red yeast rice (RYR), rich in monacolin K {beta}-hydroxy acid (MKA), is known for lipid-lowering effects, but its potential to ameliorate cardiac hypertrophy is unreported. PurposeTo investigate the effects of RYR-derived MKA on cardiac hypertrophy in spontaneously hypertensive rats (SHR) and elucidate its molecular mechanisms. MethodsSpontaneously hypertensive rats (SHR) were treated with 0.6% red yeast rice for 8 weeks to assess its effects on blood pressure, cardiac function (echocardiography), cardiac hypertrophy and fibrosis (histopathology), and multi-organ toxicity (histopathology). A multigenerational study was conducted to evaluate protective effects in offspring. Network pharmacology and transcriptomic analysis were integrated to predict molecular targets, which were subsequently validated by molecular docking and experiments. ResultsEight-week RYR treatment significantly reduced blood pressure, inhibited cardiac hypertrophy and fibrosis, and improved cardiac function without gender differences. No pulmonary, hepatic, or renal toxicity was observed. Offspring from treated parents exhibited further reduced hypertrophy upon continued treatment. Mechanistically, MKA bound ERK1/2 with high affinity, inhibiting its phosphorylation and downstream c-Fos expression, thereby downregulating hypertrophy markers. ConclusionRed yeast rice improves hypertensive cardiac hypertrophy via MKA-mediated inhibition of the ERK1/2/c-Fos pathway. Its multi-organ safety and transgenerational effects offer a novel dual-therapy strategy for hypertension and cardiac hypertrophy. Graphic abstract O_FIG O_LINKSMALLFIG WIDTH=139 HEIGHT=200 SRC="FIGDIR/small/710945v1_ufig1.gif" ALT="Figure 1"> View larger version (57K): org.highwire.dtl.DTLVardef@8225acorg.highwire.dtl.DTLVardef@775f43org.highwire.dtl.DTLVardef@10f5201org.highwire.dtl.DTLVardef@d0cd88_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SRPK3 regulates back-splicing of pre-MYOCD through Phosphorylating SRSF10 to modulate cardiac hypertrophy
xiaowei Song, Rui Cai, … Songhua Li·bioRxiv·Jun 11, 2026
- Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice
H. O. Alharbi, M. A. Hardyman, … A. Clerk·bioRxiv·Sep 7, 2022
- Animal model and therapeutic prospects for left ventricular hypertrophy and associated renal complication
- The effect of glucagon-like peptide-1 receptor agonist (GLP1RA) on hypertensive-induced heart failure with preserved ejection fraction and hypertensive cardiomyopathy
Z. Y. Zhang, S.-Y. Liao, … J. J. S.-H. Hai·bioRxiv·Feb 12, 2023
- Myocardin ablation in a cardiac-renal rat model
Anupam Mittal, Santanu Rana, … Madhu Khullar·Scientific ReportsPeer-reviewed·Apr 10, 2019
- Genetic reprogramming by brief inhibition of the renin-angiotensin system in spontaneously hypertensive rats leads to persistently reduced kidney renin and low blood pressure.
Sean Byars, Priscilla Ribeiro Prestes, … Stephen B. Harrap·bioRxiv·Jul 30, 2023